National Comprehensive Cancer Network



About NCCN

NCCN Guidelines and Compendium Updated

Flash Update sent October 24, 2012

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Penile Cancer. These NCCN Guidelines® are currently available as Version 1.2013.

  • For T1, Grade 3-4 penile cancer tumors, the primary treatment "radiotherapy ± concurrent chemotherapy (category 2B)" was revised to read: "Radiotherapy (category 2B) or Radiotherapy with concurrent chemotherapy (category 3)."
  • For T2 or greater penile cancer tumors, the primary treatment "radiotherapy ± concurrent chemotherapy (category 2B)" was clarified as being for "T2 tumors only."
  • For the management of enlarged pelvic lymph nodes, "radiotherapy with concurrent chemotherapy" was added as a treatment option.
  • The Discussion section was updated to reflect the changes in the algorithm.

 

For the complete updated versions of the NCCN Guidelines® and the NCCN Drugs and Biologics Compendium (NCCN Compendium®), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.com.

To access free NCCN Guidelines mobile apps for iPhone and Android, visit NCCN.org/mobile.

Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad. Visit NCCN.org/mobile/tablet.asp.

 

 

 

 

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved